Pediatric Patient With Concurrent Eosinophilic Esophagitis, Erosive Reflux Esophagitis, and Barrett’s Esophagus

Ishna Sharma, MD1, Chris Foster, MS2, Todd Jensen, MHS2, Fabiola Balarezo, MD3, Christine Finck, MD4, and Wael Sayej, MD5

1Department of Surgery, University of Connecticut School of Medicine, Farmington, CT
2Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT
3Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, CT
4Department of Pediatric Surgery, Connecticut Children’s Medical Center, Hartford, CT
5Department of Pediatrics, Division of Digestive Diseases, Hepatology and Nutrition, Connecticut Children’s Medical Center, Hartford, CT

ABSTRACT

Eosinophilic esophagitis and Barrett’s esophagus are believed to be separate disease processes, with erosive esophagitis leading to Barrett’s esophagus. We report a rare case of concurrent diagnoses in a pediatric patient and examine the relevant genetic profiles in the esophagus.

Figure 1. Histologic analysis of esophageal biopsies. (A) Barrett’s esophagus (BE) in the distal part of the esophagus (hematoxylin and eosin stain, 100× magnification), (B) BE in the distal part of the esophagus (Alcian blue stain, 100× magnification), (C) erosive esophagitis in the middle part of the esophagus (hematoxylin and eosin stain, 100× magnification), and (D) eosinophilic esophagitis (black arrow) in the proximal part of the esophagus (hematoxylin and eosin stain, 200× magnification).

ACG Case Rep J 2020;7:e00399. doi:10.14309/crj.0000000000000399. Published online: June 24, 2020

Correspondence: Ishna Sharma, MD (isharma@uchc.edu).
INTRODUCTION

Esophageal pathologies can occur in the pediatric population, including eosinophilic esophagitis (EoE) and Barrett’s esophagus (BE). Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) is believed to lead to BE. Although these are known to be distinct diseases with different pathophysiology and gene expression profiles, a patient can have concurrent EoE, EE, and BE. There are a few reports of patients with concurrent diagnoses. However, the gene expression profile from esophageal biopsies in a patient with concurrent EoE and BE has not been reported. We report a case of concurrent EoE, EE, and BE in a pediatric patient and examine the gene expression.

CASE REPORT

A 15-year-old morbidly obese female patient (body mass index 45) presented with multiyear symptoms of acid reflux uncontrolled by H2 blockers and proton pump inhibitors. In 2016, after a few years of management at another institution for GERD and EoE, including with topical steroids, she developed inflamed cardia-type mucosa with intestinal metaplasia and foveolar hyperplasia in the lower esophagus. In 2017 and 2018, upper endoscopy revealed Barrett’s-like mucosa in the lower esophagus with scattered ulcerations and erosions, severe esophagitis with erosions of the middle esophagus, and furrows and white specks in the upper esophagus. Biopsies were obtained from each of these 3 areas. Histologic studies demonstrated concurrent severe EoE with 30 eos/hpf, marked basal layer hyperplasia, with no granulomas and no columnar mucosa in the upper esophagus (22–25 cm); EE in the mid-esophagus (32–35 cm) with 15 eosinophils/high-power field, with no granulomas, negative periodic acid-Schiff with diastase for fungal forms, and negative immunohistochemistry for herpes simplex virus; and columnar mucosa with intestinal metaplasia containing goblet cells (Barrett’s metaplasia) and no esophageal epithelium in the lower esophagus (38–40 cm) (Figures 1 and 2). This Barrett’s metaplasia was noted to be the Prague classification C2M3.

Biopsies from the proximal, mid, and distal segments of the esophagus were also analyzed with predesigned polymerase chain reaction (PCR) assays (BioRad EoE H96 and BE H96-well disease state panels) looking at genes known to be associated with EoE and BE and were compared among the 3 segments. This showed differences in each segment (Figure 3). In the BE PCR assay, the genes AGR2, DCKL1, TFF1, VEGFA, CXCR2, EGF, IL1β, IL1RN, KR7, and DKK1 were relatively upregulated in the distal esophagus portion consistent with previous genetic studies looking at BE and relatively downregulated in the proximal esophagus portion consistent with previous genetic studies looking at EoE. GSTP1 and NOTCH1 were relatively downregulated in the distal portion, also consistent with previously described BE genotype.
In the EoE PCR assay, the genes CCL26, FOXP3, CXCL1, IL13, POSTN, TSLP, and WDR36 were relatively upregulated in the proximal portion, which is consistent with previous studies of gene expression of EoE and relatively downregulated in the distal portion, which is consistent with that of BE. The genes ANPEP, EPCAM, ERBB2, MYC, S100A2, TFF3, AURKA, BCL6, CCL2, CCL20, CXCL2, CXCL3, DKK1, and SPRR3 showed activity inconsistent with the previous literature studies of genetic expression in EoE and Barrett’s. The patient was started on a strict dairy-free diet and high-dose proton pump inhibitor therapy with significant improvement in GERD symptoms, endoscopic improvement in EoE, and EE characteristics and is receiving nutritional counseling for weight loss with surgical consultation for possible bariatric surgery.

DISCUSSION

EoE and BE are believed to be 2 distinct diseases, with different pathophysiology, management, and outcomes. Concurrent diagnosis of EoE and BE in a single patient has been previously reported. However, the gene expression profile from esophageal biopsies in these patients has not been reported. Our patient is obese with chronic reflux, which increased her risk of developing EE and BE. Although this patient does not have the typical phenotype for EoE (white male with asthma and atopic disease), her features are consistent with EoE based on endoscopic and histologic findings.

Several studies have looked at the gene expression associated with these diseases separately; however, to date, there is no known genetic study in a patient with concurrent EoE, EE, and BE. PCR studies evaluating genes known to be involved in EoE and in BE show a similar pattern in our patient corresponding to the segment of esophagus biopsied. In the upper esophagus, the patient had a gene expression most similar to that described for EoE. In the lower segment, the patient had a gene expression most similar to BE. However, of the 81 genes analyzed, 16 showed activity different than what has been described in the previous literature for either EoE and BE. This could be attributed to a combined pathophysiology in patients with concurrent diagnoses, which perhaps differentiates it from patients with exclusively one disease process. Based on these genetic profiles, the proximal esophagus pathophysiology and genetic expression is different from that of the distal esophagus, lending further evidence to the theory that EoE and BE are distinct clinical and pathologic entities.

DISCLOSURES

Author contributions: All authors contributed equally to this manuscript. I. Sharma is the article guarantor.

Financial disclosure: None to report.

Informed consent was obtained for this case report.

Received April 17, 2019; Accepted April 2, 2020

REFERENCES

1. Wolfsen HC, Hemminger LL, Achem SR. Eosinophilic esophagitis and Barrett’s esophagus with dysplasia. Clin Gastroenterol Hepatol. 2007;5(12):A18.
2. Tan LZ, Gifford AJ, Clarkson CM, Henry GM, Krishnan U. Barrett’s esophagus and eosinophilic esophagitis in a young pediatric patient with esophageal atresia. J Pediatr Surg Case Rep. 2015;3:272–5.
3. Vleggar A, Siersema PD. Barrett’s esophagus, reflux esophagitis, and eosinophilic esophagitis. Gastrointest Endosc J. 2012;76(3):496–500.
4. Rothenberg ME. Molecular genetics and cellular bases for treating eosinophilic esophagitis. Gastroenterology. 2015;148(6):1143–57.
5. Blanchard C, Stucke EM, Burwinkel K, et al. Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol. 2010;184(7):4033–41.
6. Blanchard C, Stucke EM, Rodriguez-Jimenez B, et al. A striking local esophageal cytokine expression profile in eosinophilic esophagitis. J Allergy Clin Immunol. 2011;127(1):208–17, 217.e1–7.
7. Chandramouleswaran PM, Shen D, Lee AJ, et al. Preferential secretion of thymic stromal lymphopoietin (TSLP) by terminally differentiated esophageal epithelial cells: Relevance to eosinophilic esophagitis (EoE). PLoS One. 2016;11(3):e0150968.
8. Lingblom C, Wallander J, Ingelsten M, et al. Eosinophils from eosinophilic esophagitis patients have T cell suppressive capacity and express FOXP3. Clin Exp Immunol. 2017;187(3):455–65.
9. Politi E, Angelakopoulou A, Grapsa D, et al. Filaggrin and periostin expression is altered in eosinophilic esophagitis and normalized with treatment. J Pediatr Gastroenterol Nutr. 2017;65(1):47–52.

10. Siddique AS, Corney DC, Mangray S, et al. Clinicopathologic and gene expression analysis of initial biopsies from patients with eosinophilic esophagitis refractory to therapy. J Pediatr Gastroenterol Nutr. 2017;65(1):47–52.

11. Sleiman PM, Wang ML, Cianferoni A, et al. GWAS identifies four novel eosinophilic esophagitis loci. Nat Commun. 2014;5:5593.

12. Wang J, Qin R, Ma Y, et al. Differential gene expression in normal esophagus and Barrett’s esophagus. J Gastroenterol. 2009;44(9):897–911.

13. Hao Y, Triadafilopoulou G, Sahbaie P, Young HS, Ornary MR, Lowe AW. Gene expression profiling reveals stromal genes expressed in common between Barrett’s esophagus and adenocarcinoma. Gastroenterology. 2006;131(3):925–33.

14. Darlavoix T, Seelentag W, Yan P, Bachmann A, Bosman FT. Altered expression of CD44 and DKK1 in the progression of Barrett’s esophagus to esophageal adenocarcinoma. Virchows Arch. 2009;454(6):629–37.

15. Jiang M, Li H, Zhang Y, et al. Transitional basal cells at the squamous-columnar junction generate Barrett’s esophagus. Nature. 2017;550(7677):529–33.

16. Karamchandani DM, Lehman HL, Ohanessian SE, et al. Increasing diagnostic accuracy to grade dysplasia in Barrett’s esophagus using an immunohistochemical panel for CDX2, p120ctn, c-Myc and Jagged1. Diagn Pathol. 2016;11:23.

17. Hyland PL, Hu N, Rotunno M, et al. Global changes in gene expression of Barrett’s esophagus compared to normal squamous esophagus and gastric cardia tissues. PloS One. 2014;9(4):e93219.

18. Lavery DL, Nicholson AM, Poulsom R, et al. The stem cell organisation, and the proliferative and gene expression profile of Barrett’s epithelium, replicates pyloric-type gastric glands. Gut. 2014;63(12):1854–63.

19. Lee OJ, Hong SM, Razvi MH, et al. Expression of calcium–binding proteins S100A2 and S100A4 in Barrett’s adenocarcinomas. Neoplasia. 2006;8(10):843–50.

20. Mokrowiecka A, Veits I, Falkeis C, et al. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett’s esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence. Pathol Res Pract. 2017;213(3):205–9.

21. Nishigaki H, Wada K, Tatsuuchi A, et al. ErbB2 without erbB3 expression in metaplastic columnar epithelium of Barrett’s esophagus. Digestion. 2004;70(2):95–102.

22. Peters WH, Roelofs HM, Hectors MP, Nagengast FM, Jansen JB. Glutathione and glutathione S-transferases in Barrett’s epithelium. Br J Cancer. 1993;67(6):1413–7.

23. Vega ME, Giroux V, Natsuizaka M, et al. Inhibition of Notch signaling enhances transdifferentiation of the esophageal squamous epithelium towards a Barrett’s-like metaplasia via KLF4. Cell Cycle. 2014;13(24):3857–66.

24. Wang DH, Tiwari A, Kim ME, et al. Hedgehog signaling regulates FOXA2 in esophageal embryogenesis and Barrett’s metaplasia. J Clin Invest. 2014;124(9):3767–80.

25. Whorton J, Sureban SM, May R, et al. DCLK1 is detectable in plasma of patients with Barrett’s esophagus and esophageal adenocarcinoma. Dig Dis Sci. 2015;60(2):509–13.

26. Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: Updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128:3–20.